Lexagene Holdings Inc

LexaGene Holdings reports favorable beta test results on its infectious disease diagnostic in animals

LexaGene Holdings Inc (OTCQB: LXXGF)(CVE: LXG) CEO and Founder Dr Jack Regan tells Proactive Investors the biotech company has reported favorable beta test results from its infectious disease diagnostic analyzer in animals at the Massachusetts Veterinary Referral Hospital.

Dr. Regan says the company's test returns results are produced in about one hour versus three or more days.

Quick facts: Lexagene Holdings Inc

Price: $0.60

Market: TSX-V
Market Cap: $42.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc named herein, including the promotion by the Company of Lexagene Holdings Inc in any Content on the Site, the Company...



Full interview: Lexagene takes part in beta testing it’s technology in...

Lexagene (LXG) CEO and Co-Founder Dr Jack Regan joined Steve Darling from Proactive Vancouver on Skye to discuss the beta testing Lexagene did with CDX Analytics for rapid pathogen detection in cannabis and hemp. Regan telling Proactive what the testing was looking for and the results as...

1 week, 3 days ago

2 min read